Effects of oral and transdermal estrogen therapies on circulating cytokines and chemokines in postmenopausal women with hysterectomy
article
OA: bronze
CC0
Abstract
OBJECTIVE: The aim of the present study was to determine the different effects of oral estrogen therapy (ET) and transdermal ET on changes in circulating levels of cytokines and chemokines in relationship to changes in markers of inflammation in postmenopausal women with hysterectomy. METHODS: Fifty-five postmenopausal women with hysterectomy were randomly assigned in open, parallel-group fashion to an oral ET group and a transdermal ET group. Serum levels of cytokines and chemokines were simultaneously measured using a multiplexed human cytokine assay. Serum concentrations of high-sensitive C-reactive protein, soluble vascular cell adhesion molecule-1, soluble intercellular adhesion molecule-1, and E-selectin were measured as vascular inflammation markers. RESULTS: Both oral ET and transdermal ET significantly decreased serum interleukin (IL)-7 concentrations at 12 months (P=0.020 and P=0.015 respectively). Transdermal ET decreased serum concentrations of IL-8, monocyte chemoattractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-1beta (P=0.05, P=0.019, and P=0.029), but oral ET increased IL-8 level (P=0.025). There were significant differences in percentage changes in IL-8 and MIP-1beta between the oral and transdermal ET groups. Oral ET significantly decreased E-selectin level after 12 months. CONCLUSION: Transdermal ET reduces circulating levels of IL-8, MCP-1, and MIP-1beta, while both oral ET and transdermal ET reduce circulating level of IL-7.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (36)
- doi:10.1159/000053005 via openalex
- doi:10.1055/s-0037-1615643 via openalex
- doi:10.1016/s0021-9150(99)00346-9 via openalex
- doi:10.1034/j.1600-0897.2002.01061.x via openalex
- doi:10.1016/s0015-0282(01)03223-x via openalex
- doi:10.1152/ajpendo.00269.2003 via openalex
- doi:10.1073/pnas.88.12.5252 via openalex
- doi:10.1002/eji.1830271015 via openalex
- doi:10.1016/s0008-6363(01)00461-8 via openalex
- doi:10.1038/sj.ijo.0803259 via openalex
- doi:10.1006/cyto.2002.1963 via openalex
- doi:10.3181/00379727-217-44199 via openalex
- doi:10.1210/jc.2006-1100 via openalex
- W38610698 via openalex
- W1778838840 via openalex
- doi:10.1016/s0165-2478(03)00018-x via openalex
- doi:10.1016/j.maturitas.2005.01.004 via openalex
- doi:10.1161/01.atv.0000115383.49802.0c via openalex
- doi:10.1016/j.ahj.2006.11.006 via openalex
- doi:10.1002/jlb.60.6.744 via openalex
- doi:10.1016/j.atherosclerosis.2005.12.030 via openalex
- doi:10.1016/s0002-9149(00)01116-4 via openalex
- W3143084054 via openalex
- doi:10.1111/j.1478-3231.2007.01465.x via openalex
- doi:10.1210/jcem.86.9.7799 via openalex
- doi:10.1016/j.maturitas.2006.11.002 via openalex
- doi:10.1210/jc.2007-2193 via openalex
- doi:10.1016/j.atherosclerosis.2007.06.033 via openalex
- doi:10.1016/s0735-1097(03)00156-6 via openalex
- doi:10.1210/en.2007-1521 via openalex
- doi:10.1016/0047-6374(84)90152-0 via openalex
- doi:10.1093/humrep/del245 via openalex
- doi:10.1111/j.1749-6632.2000.tb05428.x via openalex
- doi:10.1161/01.cir.0000142050.19488.c7 via openalex
- doi:10.3748/wjg.14.2818 via openalex
- doi:10.1016/j.atherosclerosis.2008.09.014 via openalex
Source provenance
- openalex
- last seen: 2026-05-13T20:07:10.637958+00:00
License: CC0
· commercial use OK